Figure 2From: Patient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb study Proportion of patients reporting device features as 'useful' or 'very useful' at Week 12 (n = 104 except for 'pre-programmed dose' [n = 103]).Back to article page